Inflammatory bowel diseases (IBD) are chronic multifactorial diseases characterized by alterations in intestinal microbiota. The current goal in the field is to define the role of the gut microbiome in the pathogenesis of IBD. The Gut microbiota composition and the related metabolites seem to affect the host healthy state both by modulating the metabolic pathways and inflammatory signaling. Accumulating evidence has suggested that intestinal microbiota represent a promising therapeutic target for IBD.
One of the important challenges is to define the role of minority groups of microbiota in IBD like fungi, virus and their interactome with bacteria. The details are as follows:
1. How fungi, bacteria and virus interact during the progression of IBD?
2. Except for the intestinal microbiota, what’s microbiota in the intestinal tissue of the mucosa?
3. Spatio-temporal analysis of microbiome in pediatric and adult IBD.
Potential topics include but are not limited to the following:
I. Bacteriome, Mycobiome and Virome in IBD;
II. The host transcriptomics during interaction with the microbiome;
III. New murine or other model organisms of IBD;
IV. Novel diagnosis biomarkers of IBD in clinic;
V. Cutting-edge technologies in characterizing IBD.
For this purpose, we are encouraging researchers to present their valuable work as the following article types: Original Research, Brief Research Report, Review, Mini Review, Clinical Trial, Data Report, Hypothesis and Theory, Methods, Opinion and Study Protocol. We will really appreciate your works and it will be a pleasure for us to receive your manuscripts.
Inflammatory bowel diseases (IBD) are chronic multifactorial diseases characterized by alterations in intestinal microbiota. The current goal in the field is to define the role of the gut microbiome in the pathogenesis of IBD. The Gut microbiota composition and the related metabolites seem to affect the host healthy state both by modulating the metabolic pathways and inflammatory signaling. Accumulating evidence has suggested that intestinal microbiota represent a promising therapeutic target for IBD.
One of the important challenges is to define the role of minority groups of microbiota in IBD like fungi, virus and their interactome with bacteria. The details are as follows:
1. How fungi, bacteria and virus interact during the progression of IBD?
2. Except for the intestinal microbiota, what’s microbiota in the intestinal tissue of the mucosa?
3. Spatio-temporal analysis of microbiome in pediatric and adult IBD.
Potential topics include but are not limited to the following:
I. Bacteriome, Mycobiome and Virome in IBD;
II. The host transcriptomics during interaction with the microbiome;
III. New murine or other model organisms of IBD;
IV. Novel diagnosis biomarkers of IBD in clinic;
V. Cutting-edge technologies in characterizing IBD.
For this purpose, we are encouraging researchers to present their valuable work as the following article types: Original Research, Brief Research Report, Review, Mini Review, Clinical Trial, Data Report, Hypothesis and Theory, Methods, Opinion and Study Protocol. We will really appreciate your works and it will be a pleasure for us to receive your manuscripts.
